HighTower Advisors
RGLS

HighTower Advisors’s Regulus Therapeutics RGLS Stock Holding History

HighTower Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-187
Closed -$14K – 2399
2018
Q2 		$14K Hold
187
– – ﹤0.01% 2123
2018
Q1 		$16K Buy
187
+10
+6% +$1.34K ﹤0.01% 2066
2017
Q4 		$22K Buy
177
+8
+5% +$1.01K ﹤0.01% 2153
2017
Q3 		$25K Buy
169
+84
+99% +$10.6K ﹤0.01% 2117
2017
Q2 		$10K Hold
85
– – ﹤0.01% 2117
2017
Q1 		$17K Buy
+85
New +$16.2K ﹤0.01% 1980

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's RGLS Position: Q3 2018 in Review

HighTower Advisors sold out of Regulus Therapeutics (RGLS) in Q3 2018, closing a stake of 187 shares — an estimated $14K sold.

HighTower Advisors first reported a position in RGLS in Q1 2017 and held it in 6 quarters. The position peaked at $25K in Q3 2017. 36 funds tracked by Wall St. Rank hold RGLS as of Q3 2018.

  • HighTower Advisors reported no remaining Regulus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • HighTower Advisors sold 187 Regulus Therapeutics shares in Q3 2018, an estimated $14K.
  • HighTower Advisors first reported a position in Regulus Therapeutics in Q1 2017 and held it in 6 quarters.
  • HighTower Advisors's Regulus Therapeutics position peaked at $25K in Q3 2017.
  • 36 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2018.

Based on HighTower Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.